Ambrx, Bristol-Myers collaborate on discovery of next-generation antibody drug conjugates
The collaboration will leverage Ambrx’s protein medicinal chemistry technology. Ambrx chief executive officer Lawson Macartney said it is the third collaboration to include another aspect of the technology
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.